ABSTRACT
Background:There is growing evidence that cytokines are the key elements in the initiation,evolution,and,ultimately,the resolution of inflammatory bowel disease (IBD).Ahns:To investigate the differences of cytokine expressions in intestinal mucosa between IBD patients and normal controls.Methods:Thirty cases of colonoscopic or enteroscopic biopsied mucosal tissue were collected from 7 normal subjects,12 ulcerative colitis (UC),and 11 definite or suspicious Crohn's disease (CD) during Jan.2014 to Dec.2014 at Shanghai East Hospital South Branch.Using the suspension chip technology,expressions of 27 cytokines in mucosal tissues were detected.Results:Most of the cytokines in intestinal mucosa of patients with IBD were decreased as compared with the normal controls,whereas the expressions of interleukin-5 (IL-5) and IL-7 were increased.Among the 27 cytokines,statistically significant differences were seen in expressions of IL-1β,IL-2,IL-15,interferon-γ-induced protein-10 (IP-10),monocyte chemoattractant protein-1 (MCP-1),macrophage inflammatory protein-1α (MIP-1α) and MIP-1β between UC,CD and normal controls (P ＜ 0.05);in addition,significant differences were seen in expressions of IL-8 and platelet-derived growth factor-BB (PDGF-BB) between CD and normal controls (P ＜ 0.05).No significant differences were observed in expressions of all 27 cytokines between UC and CD (P ＞ 0.05),as well as between active and remission stages of IBD (P ＞ 0.05).Conclusions:Expressions of IL-1β,IL-2,IL-15,IP-10,MCP-1,MIP-1α and MIP-1β are significantly down-regulated in intestinal mucosa of IBD patients.It may help to further explore the role of cytokines in IBD.
ABSTRACT
Objective To observe the effect of Lipo PGE1 and Mecobalamine and Ginkgo-dipyidamolun in the treatment of dia-betic peripheral neuropathy. Methods 60 Patients with diabetic peripheral neuropathy were divided randomly into two groups; the control group (30 cases) and the treatment group (30 cases). The patients of the treatment group were given with Lipo PGE1 100 ?g dissolved in 0.9% normal saline solution 100ml once a day intravenously, and given mecobalamine 500 ?g once a day intramuscular, and given Ginko-dipyidamolum injection 20ml dissolved in 0.9% normal saline solution 250ml once a day intravenously; and in the control group were only given with mecobalamine 500?g once a day intramuscular. Nerve conduction velocity (MNCV and SNCV) in two groups of patients was observed after 14 days treatment. Results After treatment for 14 days, the subjective symptoms and signs were significantly improved with a total effective rate of 86.7% in the treatment group versus 56.7% in the control group. Compared with the control group, the total effective rates of treatment group was significantly higher (P